Previous Study: TRIO-CIRG 011
Next Study: TRIO-US B-07
Studies & Results
TRIO029
A Phase 1, Open-Label Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors
View FDA Study
Presentations
SABCS 2018
Hoffman J, Chakrabarti J, Wainberg ZA, Plotka A
Evaluation of the effects of talazoparib on QT interval prolongation
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org
Presentations
SABCS 2018
Hoffman J, Chakrabarti J, Wainberg ZA, Plotka A
Evaluation of the effects of talazoparib on QT interval prolongation
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org